Our Work
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives
August 6, 2026
Corporate team represents the medical product development company in evaluation of a range of strategic options.
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced that it has initiated a review of strategic alternatives following receipt of a recent unsolicited acquisition proposal and multiple other expressions of interest.
Latham & Watkins LLP represents Bioventus in the review of strategic alternatives with a corporate team led by New York/Orange County partner Charles Ruck and New York partner Mark Stagliano, with associates Maddy Berg and Cristina Lombardi.